Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: Rosuvastatin compared with other statins in usual care

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 669-676

  Harley, Carolyn R ^a   Gandhi, Sanjay K ^b   Heien, Herbert ^a   McDonough, Ken ^b   Nelson, Stephanie P ^a  

^a Health Economics and Outcomes Research   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A inhibitors; Cholesterol; Diabetes; LDL C; Lipids; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DRUG EFFECT; HEALTH INSURANCE; MIDDLE AGED; PRACTICE GUIDELINE; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES COMPLICATIONS; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRAVASTATIN; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME; UNITED STATES;

EID: 41949105051     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.669     Document Type: Article

References (32)

1. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:179-82
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary on the third reports of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III). JAMA 2001;285:2486-97
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
4. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
5. Berne C, Siewert-Delle A; URANUS Study Investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005;4:7
6. Wolffenbuttel BH, Franken AA, Vincent HH; Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005;257:531-9
7. Tuomilehto J, Leiter LA, Kallend D. A review of the efficacy of rosuvastatin in patients with type 2 diabetes. Int J Clin Pract Suppl 2004;143:30-40
8. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-16
9. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-9
10. Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96
11. Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
12. Schultz JS, O'Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11:306-12
13. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9
14. Wei L, Wang J. Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-33
15. Sampalis JS, Bissonnette S, Habib R, Boukas S; Ezetrol Add-On Investigators. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Ann Pharmacother 2007;41:1345-51
16. Amarenco P, Goldstein LB, Szarek M, et al.; SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-204
17. Gould AL, Davies GM, Alemao E, et al. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther 2007;29:778-94
18. Genser B, März W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 2006;95:393-404
19. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: US Department of Health and Human Services, National Institute of Health; 2005
20. Jones PH, Davidson MH, Stein EA, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
21. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007;5:177-93
22. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123-31
23. Leiter LA, Rosenson RS, Stein E, et al.; POLARIS Study Investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007;194:e154-64
24. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - Prospective study to evaluate the Use of Low doses of the Stains Atorvastatin and Rosuvastatin (PULSAR). Trials 2006;7:35
25. Rosenson RS. HDL-C and the diabetic patient: target for therapeutic intervention? Diabetes Res Clin Pract 2005;68(Suppl 2):S36-42
26. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-78
27. Meyer JW, Schultz JS, O'Donnell JC, et al. Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health 2005;8:601-12
28. Fox KM, Gandhi SK, Ohsfeldt RL, et al. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other status among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin 2007;23:2125-33
29. Chenot F, Montant PF, Marcovitch O, et al. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest 2007;37:357-63
30. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-ana]ysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
31. Ballantyne CM, Sosef F, Duffield E; the EXPLORER Study Investigators. Efficacy and safety of rosuvastatin plus ezetimibe in high risk patients: results from the EXPLORER study. Atherosclerosis 2006;7(Suppl):552
32. Davidson MH. Rosuvastatin in elderly patients. Drugs Aging 2007;24:933-44